These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 5692134)
1. Therapeutic trials and clinical pharmacologic studies of the new terephthalanilide derivative, 2-amino-4,'4"-bis(4-methyl-2-imidazolin-2-yl)-terephthalanilide (AMIT) (NSC 66761). Van Dyk J; Kreis W; Krakoff IH; Tan CT; Cevik N; Burchenal JH Cancer Res; 1968 Aug; 28(8):1566-72. PubMed ID: 5692134 [No Abstract] [Full Text] [Related]
2. Toxicity and physiologic disposition of 2-amino-4',4"-bis(5-methyl-2-imidazolin-2-yl)terephthalanilide (NSC-66761). Philips FS; Sternberg SS; Cronin AP; Vidal PM Cancer Chemother Rep; 1966; 50(1):9-23. PubMed ID: 4956044 [No Abstract] [Full Text] [Related]
3. The antimitochondrial action of 2-choloro-4', 4"-bis(2-imidazolin-2-yl)terephthalanilide and methylglyoxal bis(guanylhydrazone). Pine MJ; DiPaolo JA Cancer Res; 1966 Jan; 26(1):18-25. PubMed ID: 5901744 [No Abstract] [Full Text] [Related]
4. Relationship of phthalanilide-lipid complexes to uptake and retention of 2-chloro-4',4"-di(2-imidazolin-2-yl)terephthalanilide (NSC 60339) by sensitive and resistant P388 leukemia cells. Yesair DW; Kohner FA; Rogers WI; Baronowsky PE; Kensler CJ Cancer Res; 1966 Feb; 26(2):202-7. PubMed ID: 5903172 [No Abstract] [Full Text] [Related]
5. Effect of 4',4"-bis(2-imidazolin-2-ylamino)terephthalanilide dihydrochloride (NSC-53306) on immune response of the rat. Oettgen HF; Binaghi RA Cancer Chemother Rep; 1965 Oct; 48():7-10. PubMed ID: 5834741 [No Abstract] [Full Text] [Related]
7. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate]. Matveev BP; Bukharkin BV Urologiia; 2001; (6):20-1. PubMed ID: 11785074 [No Abstract] [Full Text] [Related]
8. DISTRIBUTION AND EFFECTS OF 4', 4"-DI(2-IMIDAZOLIN-2-YL)TEREPHTHALANILIDE DIHYDROCHLORIDE HEMIHYDRATE AND ITS 2-CHLORO ANALOGUE IN LYMPHOCYTIC LEUKEMIAS L1210 AND P388. SIVAK A; ROGERS WI; WODINSKY I; KENSLER CJ J Natl Cancer Inst; 1964 Sep; 33():457-65. PubMed ID: 14207856 [No Abstract] [Full Text] [Related]
10. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist]. Martorana G Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170 [No Abstract] [Full Text] [Related]
11. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer]. Rusakov IG; Alekseev BIa Urologiia; 2002; (5):23-6. PubMed ID: 12402771 [No Abstract] [Full Text] [Related]
12. Physiological disposition studies of 4,4"-bis (2-imidazolin-2-yl)terephthalanilide. ROGERS WI; YORK IM; KENSLER CJ Cancer Chemother Rep; 1962 Jun; 19():67-74. PubMed ID: 14493366 [No Abstract] [Full Text] [Related]
13. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program]. Mansueto G; Longo F Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169 [No Abstract] [Full Text] [Related]
14. [Clinical application of 5-fluorouracil--with special reference to the evaluation of the intravenous administration method]. Hamaguchi E; Utsunomiya J; Hishigi S; Nakamura T Gan No Rinsho; 1968 Sep; 14(9):793-803. PubMed ID: 5750379 [No Abstract] [Full Text] [Related]
15. [Isophosphamide: study of its toxicity and immediate results with large doses]. Araujo CE; Tagle JC Prensa Med Argent; 1971 Dec; 58(40):1953-8. PubMed ID: 5137763 [No Abstract] [Full Text] [Related]
16. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule. Woodcock TM; Schneider RJ; Young CW Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893 [TBL] [Abstract][Full Text] [Related]
17. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. De Vita VT; Carbone PP; Owens AH; Gold GL; Krant MJ; Edmonson J Cancer Res; 1965 Dec; 25(11):1876-81. PubMed ID: 5858571 [No Abstract] [Full Text] [Related]
18. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Wirth M; Tyrrell C; Delaere K; Sánchez-Chapado M; Ramon J; Wallace DM; Hetherington J; Pina F; Heyns C; Borchers T; Morris T; Armstrong J; Prostate Cancer Prostatic Dis; 2005; 8(2):194-200. PubMed ID: 15931272 [TBL] [Abstract][Full Text] [Related]
19. LACK OF CROSS RESISTANCE TO THE AMIDINO AND THE UREIDO DERIVATIVES IN MOUSE LEUKEMIAS MADE RESISTANT TO 4',4"-BIS(2-IMIDAZOLIN-2-YL)-2-CHLOROTEREPHTHALANILIDE DIHYDROCHLORIDE (NSC 38280). BURCHENAL JH; LYMAN MS Proc Can Cancer Conf; 1963; 5():439-48. PubMed ID: 14278873 [No Abstract] [Full Text] [Related]
20. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. Riordan HD; Riordan NH; Jackson JA; Casciari JJ; Hunninghake R; González MJ; Mora EM; Miranda-Massari JR; Rosario N; Rivera A P R Health Sci J; 2004 Jun; 23(2):115-8. PubMed ID: 15377059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]